Vaccine advisers to the FDA decided Thursday that only strains of the JN.1 variant should be targeted by updated versions of covid vaccines that will be available next fall and winter. Separately, ...

Over the last several days, the safety and efficacy of messenger RNA, or mRNA, vaccines have come under intense scrutiny. On Tuesday, the U.S. Food and Drug Administration announced plans to limit ...

This week, mRNA vaccines are set to face intense scrutiny from critics in Congress. Here's an explainer of how we know they ...

The announcement, which followed the FDA setting new guidelines on COVID vaccine approvals, erased the stock’s gains from ...

After the FDA asked for more clinical data this month, Moderna has decided to resubmit the BLA later this year.

Moderna has withdrawn its pending application for a combination vaccine for both the flu and Covid-19, saying it will resubmit later this year once it has more data.

A new FDA framework for Covid-19 vaccines created confusion among physicians about what it means for young children ...

Respiratory syncytial virus (RSV)–associated hospitalization rates among infants in the United States were significantly lower in the first year when prevention products were widely available ...

Kennedy Jr. Moderna’s combination flu-COVID vaccine, mRNA-1083, generated stronger immune responses than standard vaccines in adults over 50 during a large phase 3 trial, according to results ...

IFLScience needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time.

The Centers for Disease Control and Prevention May 8 released an analysis that found declines in hospitalizations for infants infected with respiratory syncytial virus during the 2024-2025 RSV season ...

Nirsevimab associated with lower odds of RSV-related hospitalization, ICU admission, lower respiratory tract infection incidence. HealthDay News — Nirsevimab is effective for reducing the burden ...